Literature DB >> 10514096

Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure.

J W Langston1, L S Forno, J Tetrud, A G Reeves, J A Kaplan, D Karluk.   

Abstract

This report provides the first detailed neuropathological study of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in humans. All 3 subjects self-administered the drug under the impression it was "synthetic heroin" and subsequently developed severe and unremitting parkinsonism, which was L-dopa responsive, at least in the earlier stages of illness. Survival times ranged from 3 to 16 years. Neuropathological examination revealed moderate to severe depletion of pigmented nerve cells in the substantia nigra in each case. Lewy bodies were not present. In Patients 1 and 2, there was gliosis and clustering of microglia around nerve cells. Patient 3 had a similar picture and also showed large amounts of extraneuronal melanin. These findings are indicative of active, ongoing nerve cell loss, suggesting that a time-limited insult to the nigrostriatal system can set in motion a self-perpetuating process of neurodegeneration. Although the mechanism by which this occurs is far from clear, the precedent set by the cases could have broad implications for human neurodegenerative disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10514096     DOI: 10.1002/1531-8249(199910)46:4<598::aid-ana7>3.0.co;2-f

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  253 in total

1.  Striatal responses to partial dopaminergic lesion: evidence for compensatory sprouting.

Authors:  D D Song; S N Haber
Journal:  J Neurosci       Date:  2000-07-01       Impact factor: 6.167

2.  Acceleration of HIV dementia with methamphetamine and cocaine.

Authors:  A Nath; W F Maragos; M J Avison; F A Schmitt; J R Berger
Journal:  J Neurovirol       Date:  2001-02       Impact factor: 2.643

Review 3.  Glial cell response: A pathogenic factor in Parkinson's disease.

Authors:  Du Chu Wu; Kim Tieu; Oren Cohen; Dong-Kug Choi; Miquel Vila; Vernice Jackson-Lewis; Peter Teismann; Serge Przedborski
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

4.  Therapeutic attenuation of neuroinflammation and apoptosis by black tea theaflavin in chronic MPTP/probenecid model of Parkinson's disease.

Authors:  Annadurai Anandhan; Musthafa Mohamed Essa; Thamilarasan Manivasagam
Journal:  Neurotox Res       Date:  2012-06-06       Impact factor: 3.911

Review 5.  Neuroprotection in Parkinson's disease: an elusive goal.

Authors:  William C Koller; Maria G Cersosimo
Journal:  Curr Neurol Neurosci Rep       Date:  2004-07       Impact factor: 5.081

Review 6.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

7.  Intranasal Administration of TAT-Conjugated Lipid Nanocarriers Loading GDNF for Parkinson's Disease.

Authors:  Sara Hernando; Enara Herran; Joana Figueiro-Silva; José Luis Pedraz; Manoli Igartua; Eva Carro; Rosa Maria Hernandez
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

8.  Whole-Transcriptome Analysis of Mouse Models with MPTP-Induced Early Stages of Parkinson's Disease Reveals Stage-Specific Response of Transcriptome and a Possible Role of Myelin-Linked Genes in Neurodegeneration.

Authors:  A Kh Alieva; V S Zyrin; M M Rudenok; A A Kolacheva; M V Shulskaya; M V Ugryumov; P A Slominsky; M I Shadrina
Journal:  Mol Neurobiol       Date:  2018-02-03       Impact factor: 5.590

9.  Neuroprotective effect of diclofenac on chlorpromazine induced catalepsy in rats.

Authors:  Sadaf Naeem; Rahila Najam; Saira Saeed Khan; Talat Mirza; Bushra Sikandar
Journal:  Metab Brain Dis       Date:  2019-05-04       Impact factor: 3.584

10.  ER Stress Induced by Tunicamycin Triggers α-Synuclein Oligomerization, Dopaminergic Neurons Death and Locomotor Impairment: a New Model of Parkinson's Disease.

Authors:  Valentín Cóppola-Segovia; Clarissa Cavarsan; Flavia G Maia; Anete C Ferraz; Lia S Nakao; Marcelo Ms Lima; Silvio M Zanata
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.